Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 科学研究和技术服务业
Company Introduction 公司是一家专注于重组蛋白应用解决方案的高新技术企业，主营业务为靶点及因子类蛋白、重组抗体、酶及试剂的研发、生产、销售，并提供相关技术服务。公司作为医疗健康与生命科学领域的上游供应商，致力于为下游客户提供及时、稳定、优质的产品及服务，助力全球生物医药企业和研究机构的技术与产品创新升级。 公司提供的产品与服务可应用于生物药、生命科学基础研究、体外诊断、mRNA疫苗药物、生命科学基础研究等诸多领域。基于长期的实践经验及技术开发积累，公司综合了23项核心技术搭建了公司技术平台。公司打破传统蛋白设计理念，实现定向进化蛋白质性能，根据客户需求研发生产出高性能抗体及符合药企质量体系生产要求的酶及试剂。同时，公司建立了规模化生产平台，突破了相关产品从实验室到大规模生产的瓶颈。截至本招股书签署日，公司已经推出了超过7,700种产品及服务项目，包括了2,900余种重组蛋白产品、60余种重组抗体产品，500余种酶及试剂产品、成功交付了4,500余项CRO服务项目。 公司深耕重组蛋白行业十余年，为包括亚洲、欧洲、美洲、大洋洲在内的数千家企业与科研机构提供优质的产品与服务。凭借公司在业界树立的良好口碑，公司与罗氏、恒瑞医药、沃森生物、艾博生物、雅培、万孚生物、明德生物等国内外知名企业建立了合作关系，助力全球生物医药企业和体外诊断企业的研发和生产。同时，公司高度关注行业前沿研究，为广大科研单位提供产品与技术支持，帮助生命科学研究顺利进行。哈佛大学、斯坦福大学、杜克大学、美国国立卫生院、加州理工学院、南洋理工大学、中国科学院、清华大学、北京大学、复旦大学等众多高校和科研机构使用公司产品作为试验试剂并据此发表诸多论文，相关产品获得了应用市场及科研机构的高度认可，产品及服务内容被上千篇SCI论文引用。
Main Business 靶点及因子类蛋白、重组抗体、酶及试剂的研发、生产、销售，并提供相关技术服务。
Legal Representative 朱化星
Top Executives
董事长：朱化星
董事：王英明,邹方平,王笃强,赵玉剑,陆幼辰
独立董事：金坚,张宗新,宋夏云
Top 5 Shareholder
Shareholder name Nature Holding Date
上海欣百诺生物科技有限公司限售股43.26%31/03/2024
吴江东运创业投资有限公司流通A股14.42%31/03/2024
苏州帆岸企业管理合伙企业（有限合伙）限售股5.64%31/03/2024
苏州玫岸企业管理合伙企业（有限合伙）限售股2.37%31/03/2024
苏州工业园区启华六期创业投资合伙企业（有限合伙）限售股2.25%31/03/2024
Company Secretary 王笃强
Solicitors 北京德恒律师事务所
Auditors 容诚会计师事务所（特殊普通合伙）
Tel No 0512-63919116;021-50798028
Fax No 0512-63917398-805;021-50798028-8088
Website www.novoprotein.com.cn
Email IR@novoprotein.com.cn
Company Address
Register: 江苏省苏州市吴江经济技术开发区云创路228号3层，4层
Office: 江苏省苏州市吴江经济技术开发区云创路228号3层，4层
Listing Date 29/09/2022
Shares Capital
Shares Capital: 70,175,439
Total A Share: 70,175,439
Listed A Share: 29,695,536
Non-tradable A Share: 40,479,903
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.180
DPS(RMB)* ¥ 0.500
NBV Per Share(RMB)* ¥ 31.186
Market Capitalization(RMB) 1.131B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.